 |
| An illustration of the Memo 3D ReChord annuloplasty ring--Courtesy of Sorin |
Italy's Sorin Group says its just-cleared Memo 3D ReChord semirigid annuloplasty ring for mitral valve repair will simplify the procedure and enable surgeons to achieve reproducible results.
Sorin touted the device's new features including its chordal guide system, a Carbofilm coating to improve compatibility with blood (hemocompatibility) and design that it says preserves the motion of the native annulus, which is a ringlike structure in the heart.
The first implantation of the ring in the U.S. was performed by Dr. Steven F. Bolling, professor of cardiac surgery at the University of Michigan Health System.
"The Memo 3D ReChord implant performed by Prof. Bolling and his team represents the first step in strategically growing our presence in the US mitral valve repair market," said the president of the company's cardiac surgery unit Michel Darnaud in a statement. "The most gratifying aspect of this first U.S. experience is to see Sorin's technology deliver on the Company's commitment to increase product standards for physicians while improving patient outcomes."
In the first 9 months of 2014, Sorin reported revenue of €550.4 million ($675.6 million), with all but €1.9 million ($2.3 million) coming from its cardiac surgery and cardiac rhythm management units.
In April, Sorin received FDA PMA supplement approval for its latest aortic heart valve, the Mitroflow Aortic Pericardial Heart Valve. And last year, Sorin picked up the FDA's blessing to market its SmartView remote monitoring system, which allows physicians to keep tabs on patients with implanted cardiac devices while they're at home.
- read the release